Sub: Regulation 39(3) of the SEBI (Listing Obligations
and Disclosure Requirements) Regulations,
2015 for issuance of Letter of Confirmation in
lieu of Duplicate Share Certificate
Dear Sir/Madam,
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), read with SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022, kindly note that the Company has issued the Letter of Confirmation in lieu of Duplicate Share Certificate to the following shareholder:-
Folio
Name
of
Old
Cert.
Distinctive No.
No. of
New
No.
Shareholder
No.
shares
Cert.
No.
KISTURI DEVI
58551-58554
9920071-9920195
125
86409
035419
83678-83678
13637720-13637844
125
BIHANI
85667-85667
26138361-26139110
750
This is for
your information and
records.
Thanking you,
Yours faithfully,
FOR AARTI DRUGS LIMITED
RUSHIKESH VIVEK DEOLE
Digitally signed by RUSHIKESH VIVEK DEOLE DN: c=IN, o=PERSONAL, title=5599, pseudonym=52288d43536c4230831c2e75cd4b8c59, 2.5.4.20=073813c4edff683f8b6ec3cb4e69ca6d8d4f725 8a44f635abc18581eaa522821, postalCode=421301, st=Maharashtra, serialNumber=9b60f64457feab7f455d17463ebe710861 bf01b575f6fc0484483273dabfc17f, cn=RUSHIKESH
VIVEK DEOLE
Date: 2022.12.27 12:16:53 +05'30'
RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M.No.: A54527
Attachments
Original Link
Original Document
Permalink
Disclaimer
Aarti Drugs Ltd. published this content on 27 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 December 2022 11:19:44 UTC.
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
AARTI DRUGS LIMITED 
